A Phase III trial of Regeneron Pharmaceuticals Inc.’s evinacumab in homozygous familial hypercholesterolemia (HoFH) has met its primary endpoint.
The study showed intravenous administration of the angiopoietin-like 3 (ANGPTL3) antibody produced a 49% drop in low-density lipoprotein (LDL) in patients with HoFH, a genetic disease that causes elevated levels of the harmful form of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?